Literature DB >> 21036837

Outcomes of multidrug-resistant tuberculosis among binational cases in El Paso, Texas.

Gustavo Ferrer1, Carlos Acuna-Villaorduna, Miguel Escobedo, Esteban Vlasich, Manuel Rivera.   

Abstract

In the United States, multidrug-resistant tuberculosis (MDR-TB) is more commonly seen among foreign-born patients. We report outcomes for 46 patients with MDR-TB who were born in Mexico and treated along the United States-Mexico border. According to our definition, 30 were cured, 3 showed treatment failure, 3 died, and 10 abandoned treatment. Multidrug-resistant tuberculosis can be successfully treated on an ambulatory basis.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21036837      PMCID： PMC2963969          DOI： 10.4269/ajtmh.2010.10-0145

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  13 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

2.  Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.

Authors:  K F Laserson; L E Thorpe; V Leimane; K Weyer; C D Mitnick; V Riekstina; E Zarovska; M L Rich; H S F Fraser; E Alarcón; J P Cegielski; M Grzemska; R Gupta; M Espinal
Journal:  Int J Tuberc Lung Dis       Date:  2005-06       Impact factor: 2.373

Review 3.  Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control.

Authors:  Giovanni Battista Migliori; Morgan D'Arcy Richardson; Giovanni Sotgiu; Christoph Lange
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

4.  Preventing and controlling tuberculosis along the U.S.-Mexico border.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2001-01-19

5.  Public-private collaboration for multidrug-resistant tuberculosis control in New York City.

Authors:  S S Munsiff; S D Ahuja; J Li; C R Driver
Journal:  Int J Tuberc Lung Dis       Date:  2006-06       Impact factor: 2.373

6.  Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997.

Authors:  M Narita; P Alonso; M Lauzardo; E S Hollender; A E Pitchenik; D Ashkin
Journal:  Chest       Date:  2001-08       Impact factor: 9.410

7.  Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

Authors:  Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

8.  Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis.

Authors:  Edward D Chan; Valerie Laurel; Matthew J Strand; Julanie F Chan; Mai-Lan N Huynh; Marian Goble; Michael D Iseman
Journal:  Am J Respir Crit Care Med       Date:  2004-01-23       Impact factor: 21.405

9.  Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.

Authors:  M Goble; M D Iseman; L A Madsen; D Waite; L Ackerson; C R Horsburgh
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245

10.  Tuberculosis among foreign-born persons in the United States.

Authors:  Kevin P Cain; Stephen R Benoit; Carla A Winston; William R Mac Kenzie
Journal:  JAMA       Date:  2008-07-23       Impact factor: 56.272
View more
  7 in total

1.  Border Lookout: Enhancing Tuberculosis Control on the United States-Mexico Border.

Authors:  Carla DeSisto; Kelly Broussard; Miguel Escobedo; Denise Borntrager; Francisco Alvarado-Ramy; Stephen Waterman
Journal:  Am J Trop Med Hyg       Date:  2015-08-24       Impact factor: 2.345

2.  A population-based study of first and second-line drug-resistant tuberculosis in a high-burden area of the Mexico/United States border.

Authors:  Pola Becerril-Montes; Salvador Said-Fernández; Julieta Luna-Herrera; Guillermo Caballero-Olín; José Antonio Enciso-Moreno; Herminia Guadalupe Martínez-Rodríguez; Gerardo Padilla-Rivas; Elsa Nancy-Garza-Treviño; Gloria María Molina-Salinas
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-04       Impact factor: 2.743

3.  Interferon Gamma-Based Detection of Latent Tuberculosis Infection in the Border States of Nuevo Leon and Tamaulipas, Mexico.

Authors:  Eyal Oren; Gabriela Alatorre-Izaguirre; Javier Vargas-Villarreal; Maria Guadalupe Moreno-Treviño; Javier Garcialuna-Martinez; Francisco Gonzalez-Salazar
Journal:  Front Public Health       Date:  2015-09-30

4.  Detection of latent tuberculosis infection among migrant farmworkers along the US-Mexico border.

Authors:  E Oren; M H Fiero; E Barrett; B Anderson; M Nuῆez; F Gonzalez-Salazar
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

Review 5.  Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis.

Authors:  Laura B Nellums; Kieran Rustage; Sally Hargreaves; Jon S Friedland
Journal:  BMC Med       Date:  2018-02-22       Impact factor: 8.775

Review 6.  Association between Directly Observed Therapy and Treatment Outcomes in Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.

Authors:  Jia Yin; Jinqiu Yuan; Yanhong Hu; Xiaolin Wei
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

7.  Patient support for tuberculosis patients in low-incidence countries: A systematic review.

Authors:  Sarah van de Berg; Niesje Jansen-Aaldring; Gerard de Vries; Susan van den Hof
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.